These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

528 related items for PubMed ID: 30780194

  • 1. Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial.
    Lu B, Wang J, Li J, Liu L, Chen Y.
    Helicobacter; 2019 Apr; 24(2):e12566. PubMed ID: 30780194
    [Abstract] [Full Text] [Related]

  • 2. Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
    Zhang D, Ke L, Ni Z, Chen Y, Zhang LH, Zhu SH, Li CJ, Shang L, Liang J, Shi YQ.
    Medicine (Baltimore); 2017 Aug; 96(32):e7697. PubMed ID: 28796053
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM, Fang YJ, Chen CC, Bair MJ, Chang CY, Lee YC, Chen MJ, Chen CC, Tseng CH, Hsu YC, Lee JY, Yang TH, Luo JC, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hu WH, Chen YN, Sheu BS, Lin JT, Wu JY, El-Omar EM, Wu MS, Taiwan Gastrointestinal Disease and Helicobacter Consortium.
    Lancet; 2016 Nov 12; 388(10058):2355-2365. PubMed ID: 27769562
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
    Magaret N, Burm M, Faigel D, Kelly C, Peterson W, Fennerty MB.
    Dig Dis; 2001 Nov 12; 19(2):174-8. PubMed ID: 11549829
    [Abstract] [Full Text] [Related]

  • 9. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial.
    Macías-García F, Bastón-Rey I, de la Iglesia-García D, Calviño-Suárez C, Nieto-García L, Domínguez-Muñoz JE.
    Helicobacter; 2019 Feb 12; 24(1):e12546. PubMed ID: 30346636
    [Abstract] [Full Text] [Related]

  • 10. 14 day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: a multicentre, non-inferiority, randomized trial.
    Liou JM, Chen CC, Fang YJ, Chen PY, Chang CY, Chou CK, Chen MJ, Tseng CH, Lee JY, Yang TH, Chiu MC, Yu JJ, Kuo CC, Luo JC, Hsu WF, Hu WH, Tsai MH, Lin JT, Shun CT, Twu G, Lee YC, Bair MJ, Wu MS, Members of the Taiwan Gastrointestinal Disease and Helicobacter Consortium.
    J Antimicrob Chemother; 2018 Sep 01; 73(9):2510-2518. PubMed ID: 29846605
    [Abstract] [Full Text] [Related]

  • 11. A randomised controlled clinical study of standard triple therapy, bismuth-based quadruple therapy and sequential therapy for Helicobacter pylori infection in children.
    Miao R, Chen J, Gao S, Wang L, Zhou W, Wan C, Wang Z.
    BMC Pediatr; 2024 Aug 23; 24(1):543. PubMed ID: 39180014
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L, Oderda G, Bazzoli F, Moayyedi P.
    Cochrane Database Syst Rev; 2013 Dec 11; (12):CD008337. PubMed ID: 24338763
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial.
    Su J, Zhou X, Chen H, Hao B, Zhang W, Zhang G.
    Medicine (Baltimore); 2017 Feb 11; 96(7):e5859. PubMed ID: 28207505
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication: a prospective, randomized study.
    De Francesco V, Pontone S, Bellesia A, Serviddio G, Panetta C, Palma R, Zullo A.
    Dig Liver Dis; 2018 Feb 11; 50(2):139-141. PubMed ID: 29089267
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China.
    Hu JL, Yang J, Zhou YB, Li P, Han R, Fang DC.
    Saudi J Gastroenterol; 2017 Feb 11; 23(5):275-280. PubMed ID: 28937021
    [Abstract] [Full Text] [Related]

  • 19. New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese prospective, randomized, multicentre trial.
    Xie Y, Pan X, Li Y, Wang H, Du Y, Xu J, Wang J, Zeng Z, Chen Y, Zhang G, Wu K, Liu D, Lv N.
    J Antimicrob Chemother; 2018 Jun 01; 73(6):1681-1687. PubMed ID: 29596646
    [Abstract] [Full Text] [Related]

  • 20. Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori.
    Yang J, Zhang Y, Fan L, Zhu YJ, Wang TY, Wang XW, Chen DF, Lan CH.
    Am J Gastroenterol; 2019 Mar 01; 114(3):437-445. PubMed ID: 30807294
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.